Novel oxazolo[3',2':1,2]pyrrolo[3,4-d]pyridazines and imidazolo[1',2':1,2]pyrrolo[3,4-d]pyridazines: Synthesis and biological evaluation

Archiv der Pharmazie

Volumn 329, Issue 8-9, 1996, Pages 403-407

  Barth, Birgit ^a   Dierich, Manfred ^c   Heinisch, Gottfried ^a   Matuszczak, Barbara ^a   Mereiter, Kurt ^b   Soder, Josef ^a   Stoiber, Heribert ^c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

2,3 dihydro 9b phenylimidazolo 1',2':1,2 pyrrolo 3,4 d pyridazin 5(9bH) ones; 2,3 dihydro 9b phenyloxazolo 3',2':1,2 pyrrolo 3,4 d pyridazin 5(9bH) ones; HIV 1 reverse transcriptase inhibition

Indexed keywords

ANTIVIRUS AGENT; NEVIRAPINE; OXAZOLE DERIVATIVE; OXAZOLO[3',2':1,2]PYRROLO[3,4 D]PYRIDAZINE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRROLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFRARED SPECTROPHOTOMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REACTION ANALYSIS; X RAY ANALYSIS; DRUG ANTAGONISM; SYNTHESIS;

ANTIVIRAL AGENTS; HIV-1 REVERSE TRANSCRIPTASE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0030207183     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/ardp.19963290806     Document Type: Article

References (18)

1. Part 78: G. Heinisch, T. Langer, J. Tonnel, J. Heterocyclic Chem. submitted.
2. E. De Clercq, Clin. Microbiol. Rev. 1995, 8, 200-239.
3. A. Mertens, H. Zilch, B. König, W. Schäfer, T. Poll, W. Kampe, H. Seidel, U. Leser, H. Leinert, J. Med. Chem. 1993, 36, 2526-2535.
4. For recent reviews see: a) E. De Clercq, Exp. Opin. Invest. Drugs, 1994, 3, 253-271; b) E. De Clercq, Int. J. Immunotherapy 1994, 10, 145-158.
5. For recent reviews see: a) E. De Clercq, Exp. Opin. Invest. Drugs, 1994, 3, 253-271; b) E. De Clercq, Int. J. Immunotherapy 1994, 10, 145-158.
6. For a crystal structure of HIV-1 reverse transcriptase complexed with an inhibitor see: L.A. Kohlstaedt, J. Wang, J.M. Friedman, P.A. Rice, T.A. Steitz, Science 1992, 256, 1783-1790.
7. W. Schäfer, W.-G. Friebe, H. Leinert, A. Mertens, T. Poll, W. v.d. Saal, H. Zilch, B. Nuber, M.L. Ziegler, J. Med. Chem. 1993, 36, 726-732.
8. For a recent review see: N. Haider, G. Heinisch, Heterocycles 1993, 35, 519-538.
9. G. Heinisch, I. Kirchner, I. Kurzmann, G. Lötsch, R. Waglechner, Arch. Pharm. (Weinheim) 1983, 316, 508-515.
10. P. Aeberli, W.J. Houlihan, J. Org. Chem. 1969, 34, 165-170.
11. G. Heinisch, I. Kirchner, Monatsh. Chem. 1979, 110, 365-376.
12. a) M. Fuxreiter, A. Csámpai, J. Császár, Heterocycles 1994, 38, 1453-1457;
13. b) R.C. Petter, S. Banerjee, S. Englard, J. Org. Chem. 1990, 55, 3088-3097.
14. K.D. Hargrave, J.R. Proudfoot, K.G. Grozinger, E. Cullen, S.R. Kapadia, U.R. Patel, V.U. Fuchs, S.C. Mauldin, J. Vitous, M.L. Behnke, J.M. Klunder, K. Pal, J.W. Skiles, D.W. McNeil, J.M. Rose, G.C. Chow, M.T. Skoog, J.C. Wu, G. Schmidt, W.W. Engel, W.G. Eberlein, T.D. Saboe, S.J. Campbell, A.S. Rosenthal, J. Adams, J. Med. Chem. 1991, 34, 2231-2241.
15. W.J. Leanza, H.J. Becker, E.F. Rogers, J. Am. Chem. Soc. 1953, 75, 4086-4087.
16. G. Heinisch, Monatsh. Chem. 1973, 104, 953-962.
17. G.M. Sheldrick, SHELX76. Program for crystal structure determination. Univ. of Cambridge, England, 1976.
18. G.M. Sheldrick, SHELXL93. Program for crystal structure refinement. Univ. of Göttingen, FRG, 1993.